Sanara MedTech Inc.

Equities

SMTI

US79957L1008

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
32.35 USD +0.43% Intraday chart for Sanara MedTech Inc. -4.26% -21.29%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sanara Medtech Inc. Announces $55 Million Debt Facility CI
Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer MT
Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024 CI
Cantor Fitzgerald Cuts Price Target on Sanara MedTech to $44 From $49, Maintains Overweight Rating MT
Transcript : Sanara MedTech Inc., Q4 2023 Earnings Call, Mar 26, 2024
Earnings Flash (SMTI) SANARA MEDTECH Posts Q4 Revenue $17.7M, vs. Street Est of $16.5M MT
Sanara MedTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sanara MedTech Reports Higher Preliminary Q4 Revenue MT
Sanara MedTech Inc. Announces Unaudited Preliminary Net Revenue Results for the Fourth Quarter and Full-Year 2023 CI
Sanara MedTech Secures Exclusive Licensing Deal with Tufts University for 18 Collagen Peptides MT
Cantor Fitzgerald Adjusts Price Target on Sanara MedTech to $49 From $59, Maintains Overweight Rating MT
Transcript : Sanara MedTech Inc., Q3 2023 Earnings Call, Nov 14, 2023
Sanara MedTech Q3 Loss Narrows, Revenue Rises; Shares Fall After Hours MT
Earnings Flash (SMTI) SANARA MEDTECH Reports Q3 Revenue $16M, vs. Street Est of $18.8M MT
Sanara MedTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sanara MedTech Inc. Announces BIASURGE Advanced Surgical Solution Updates CI
Transcript : Sanara MedTech Inc., Q2 2023 Earnings Call, Aug 15, 2023
Earnings Flash (SMTI) SANARA MEDTECH Reports Q2 Revenue $15.8M, vs. Street Est of $16.9M MT
Sanara MedTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sanara MedTech Acquires Selected Assets Related to Its Collagen Products Business MT
Sanara MedTech Inc. acquired Certain Assets Related to its Collagen Products Business from Applied Nutritionals, LLC, The Hymed Group Corporation, and Dr. George Petito for 25.3 million. CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell 3000E Growth Index CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell Small Cap Completeness Index CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell 2500 Index CI
Sanara MedTech Inc.(NasdaqCM:SMTI) added to Russell 3000 Index CI
Chart Sanara MedTech Inc.
More charts
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
32.35 USD
Average target price
44 USD
Spread / Average Target
+36.01%
Consensus
  1. Stock Market
  2. Equities
  3. SMTI Stock
  4. News Sanara MedTech Inc.
  5. Cantor Fitzgerald Cuts Price Target on Sanara MedTech to $44 From $49, Maintains Overweight Rating